Laboratoires Anios, which is backed by Ardian, has acquired Deren, a Turkey-based maker of hospital disinfectants. No financial terms were disclosed.
April 2015. Laboratoires Anios, a leading European provider of disinfectant products for the hospital sector, and a key player for the industrial and catering /accommodation sectors, announces the acquisition of Deren. This is Anios’ second build-up, and first acquisition abroad, since the family business was acquired in December 2013 by a consortium composed of Bertrand Letartre, Thierry Letartre and Ardian, the independent investment company.
Based in Istanbul and founded by Mahmut Özdemir in 2003, Deren is Turkey’s leading hospital disinfectant manufacturer. Such acquisition will strengthen Anios position on a sound and dynamic Turkish market, and expand company’s production and development capacity.
Deren has grown to become a market leader with a specific focus on public hospitals, having developed a range of locally renowned products in the 12 years since its creation. The company will add to Anios’ existing Turkish presence, established by its Ankara-based subsidiary, which has operated in the Turkish private hospital market for 10 years.
The combination will accelerate both companies’ development perspectives on both public and private markets, benefitting from complementary product lines and locations. The acquisition also provides Anios with a competitive local production base, ideally located in Istanbul.
Such common ambition is also the result of a close collaboration between Anios’ management and Mahmut Özdemir, Deren’s founder. The two companies will take advantage from their mutual skills and know-how: Anios’ cutting-edge R&D and outstanding quality standards of the Luce Letartre Research and Development Centre, and Deren’s field expertise and knowledge of the Turkish market.
Bertrand and Thierry Letartre said: “With a number of development projects in progress, 2015 promises to be a landmark year which will see accelerated international growth for the enlarged group.”
Anios confirms objective to reach 50% of sales abroad by 2020, positioning the group among the world leaders in the disinfection market.
ABOUT LABORATOIRES ANIOS
No. 1 in France and the European leader in the market for disinfection.
Laboratoires Anios manufactures cleaning and disinfection products since 1898, and is a major player in hygiene, for hospitals, clinics and medical professions. Laboratoires Anios is also present in food-processing, cosmetics, and pharmaceutics industries, as well as in the communities linked to accommodation and catering, in France and in over 80 countries. With c.700 employees, two production sites and a 1,000 square meters research center in northern France, as well as a production site in southern France, one in Italy and one in Argentina, Laboratoires Anios produces 120,000 bottles per day and has 12,000 business customers.
No. 1 in the Turkish disinfection market
Based in Istanbul, Deren is the leader in disinfection products for Turkish hospitals and clinics, with a range of 60 products; it also produces dialysis products. The company, founded in 2003 by Mahmut Özdemir, employs 40 people.
Founded in 1996 and directed by Dominique Senequier, Ardian is an independent investment company which manages and/or advises on $50 billion of assets in Europe, North America and Asia. The company has always placed the entrepreneurial spirit at the heart of its approach and offers international investors superior performance, while contributing to the growth of companies throughout the world. The Ardian investment philosophy is based on three pillars: excellence, loyalty and entrepreneurship. Ardian employees form the largest group of shareholders. Indeed 80% of them have chosen to invest in the company, reflecting their confidence in the strategy implemented by the management team.
Ardian is based on a strong international network, with over 350 employees in ten offices in Beijing, Frankfurt, Jersey, London, Luxembourg, Milan, New York, Paris, Singapore and Zurich. The company offers its 355 investors a diversified range of funds covering all asset classes, with Direct Funds including Infrastructure, Mid Cap Buyout, Expansion, Ardian Growth, Co-Investment Fund of Funds (primary, secondary and early secondary) and Private Debt.